| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2012-07-09 | 40% of VCN Bioscience (Spain) | Grifols (Spain) | undisclosed | Cancer-Oncology |
| 2012-07-06 | Exprimo (Belgium) | SGS (Switzerland) | undisclosed | services |
| 2012-06-28 | Corimmun (Germany) | Janssen-Cilag GmbH (J&J) (USA) | undisclosed | Drug development |
| 2012-06-27 | Prestizia (France) | Theradiag (France) | € 2.5 million | Diagnostic - Infectious diseases - Cancer - Oncology - Autoimmune diseases |
| 2012-06-13 | Proximagen (UK) | Upsher-Smith Laboratories (USA) | SNC diseases |
|
| 2012-06-05 | Israeli Hepatitis B Vaccine Manufacturer (Israel) | OPKO Health (USA) | Financial terms of the transaction were not disclosed. | Vaccines |
| 2012-05-18 | Vitrology Limited (UK) | SGS (Switzerland) | undisclosed | biosafety services |
| 2012-05-17 | Dako (Denmark) | Agilent Technologies (USA) | $2.2 billion (€1.72 billion) | diagnostics |
| 2012-05-03 | Kensey Nash (USA) | DSM (The Netherlands) | $ 360 million (about €275 million) | biomedical business |
| 2012-05-03 | AmniSure International (USA - MA) | Qiagen (The Netherlands) | undisclosed | diagnostic |
| 2012-04-26 | EUSA Pharma (USA) | Jazz Pharmaceuticals (Ireland) | $680 million (€543million) in cash plus a potential $50 million (€37.9 million) milestone payment | Oncology |
| 2012-04-25 | Mustafa Nevzat Pharmaceuticals (Turkey) | Amgen (USA) | US $700 million (€ 529.4 million) | Pharmaceuticals |
| 2012-04-23 | Pfizer Nutrition (USA) | Nestlé (Switzerland) | $11.85 billion (€ 9 billion) | Nutrition |
| 2012-04-23 | Ardea Biosciences (USA) | AstraZeneca (UK) | $1.26 billion (€ 0.95 billion) | Cancer |
| 2012-04-16 | 10,000,000 shares of Theravance common stock (USA) | GSK (UK) | $212,887,000 (€ 159861,106) | |
| 2012-04-12 | Pervasis Therapeutics (USA) | Shire (UK - USA) | Shire will provide Pervasis with an upfront payment, plus potential post-closing milestone payments that are dependent on Shire’s achievement of certain clinical development, regulatory and sales targets. | regenerative medicine |
| 2012-04-02 | Newport Laboratories (USA) | Merial (France) | undisclosed | veterinary medicine |
| 2012-03-21 | Altacor (UK) | NicOx (France) | £2 million (approximately €2.4 million) and £9 million (approximately €10.8 million) to be paid in NicOx shares, cash or a combination of cash and shares at NicOx’s discretion. | Ophtalmology |
| 2012-03-16 | Pluromed (USA) | Sanofi (France) | undisclosed | Biosurgery |
| 2012-03-15 | Éclat Pharmaceuticals (USA) | Flamel Technologies (France) | specialty pharmaceuticals |
